HMBD-002

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameHMBD-002
Drug Alias NameHMBD-002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionV-domain Ig suppressor of T-cell activation inhibitors
TargetsV-domain Ig suppressor of T-cell activation
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesHummingbird Bioscience
China Registration ClassN/A

Develop Information

Active CompaniesPercheron Therapeutics LtdHummingbird BioscienceMerck Sharp & Dohme LLC
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A